| Dova Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The United States Food and Drug Administration has approved DOPTELET (avatrombopag), which is an orally administered thrombopoietin receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. Co. is also conducting a trial in chemotherapy-induced thrombocytopenia. We show 11 historical shares outstanding datapoints in our DOVA shares outstanding history coverage, used to compute DOVA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DOVA market cap history over the course of time is important for investors
interested in comparing DOVA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DOVA versus a peer is one thing; comparing
DOVA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DOVA can fluctuate over the course of history.
With this page we aim to empower investors researching DOVA by allowing them to research the DOVA market cap history.